Skip to content

Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00223483
Enrollment
512
Registered
2005-09-22
Start date
2005-03-31
Completion date
2021-07-14
Last updated
2021-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers, Hematologic Diseases

Keywords

Hematologic Diseases, Genomics, Cytokines, Chemokines, Receptors

Brief summary

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

Detailed description

This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.

Interventions

GENETICIsolation of genomic DNA

One time blood draw

Sponsors

US Department of Veterans Affairs
CollaboratorFED
The University of Texas Health Science Center at San Antonio
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Must be able to give blood * Must be able to give informed consent * Signed, written informed consent

Exclusion criteria

* Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders. * Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.

Design outcomes

Primary

MeasureTime frame
Repository collection of plasma and serum for future analysis.12 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026